---
title: Chemsex Engagement and HIV Biomedical Prevention in MSM
nct_id: NCT05031832
overall_status: COMPLETED
sponsor: Chinese University of Hong Kong
study_type: OBSERVATIONAL
primary_condition: Recreational Drug Use
countries: Hong Kong
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05031832.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05031832"
ct_last_update_post_date: 2025-01-23
last_seen_at: "2026-05-12T06:37:04.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Chemsex Engagement and HIV Biomedical Prevention in MSM

**Official Title:** The Interrelationship Between Chemsex Engagement and HIV Biomedical Prevention in MSM

**NCT ID:** [NCT05031832](https://clinicaltrials.gov/study/NCT05031832)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 733
- **Lead Sponsor:** Chinese University of Hong Kong
- **Conditions:** Recreational Drug Use
- **Start Date:** 2021-06-01
- **Completion Date:** 2024-12-31
- **CT.gov Last Update:** 2025-01-23

## Brief Summary

HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* aged 18 or above
* male
* have had sex with men since 2019
* could be communicated in English or Chinese

Exclusion Criteria:

* failed to provide consent
```

## Arms

- **HIV-negative**
- **HIV-positive**

## Interventions

- **HIV test** (DIAGNOSTIC_TEST) — HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status

## Primary Outcomes

- **pre-exposure prophylaxis coverage** _(time frame: 6 months)_ — proportion of HIV-negative MSM taking pre-exposure prophylaxis; based on self-reported data in questionnaire
- **Good antiretroviral therapy adherence** _(time frame: 2 years)_ — proportion of HIV-positive MSM with good antiretroviral therapy adherence; based on self-reported data (CD4 count, viral load level, history of stoppoing ART / missing doses) in questionnaire
- **Drug use pattern** _(time frame: 6 months)_ — types of drugs taken for chemsex engagement (taking before or during sex); based on self-reported data in questionnaire

## Locations (1)

- The Chinese University of Hong Kong, Hong Kong, Hong Kong, Hong Kong

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the chinese university of hong kong|hong kong|hong kong|hong kong` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05031832.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05031832*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*